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Objective: To determine which preoperative breast magnetic resonance imaging (MRI) findings and clinicopathologic 
features are associated with positive resection margins at the time of breast-conserving surgery (BCS) in patients with 
breast cancer.
Materials and Methods: We reviewed preoperative breast MRI and clinicopathologic features of 120 patients (mean age, 
53.3 years; age range, 27−79 years) with breast cancer who had undergone BCS in 2015. Tumor size on MRI, multifocality, 
patterns of enhancing lesions (mass without non-mass enhancement [NME] vs. NME with or without mass), mass 
characteristics (shape, margin, internal enhancement characteristics), NME (distribution, internal enhancement patterns), 
and breast parenchymal enhancement (BPE; weak, strong) were analyzed. We also evaluated age, tumor size, histology, 
lymphovascular invasion, T stage, N stage, and hormonal receptors. Univariate and multivariate logistic regression analyses 
were used to determine the correlation between clinicopathological features, MRI findings, and positive resection margins.
Results: In univariate analysis, tumor size on MRI, multifocality, NME with or without mass, and segmental distribution of 
NME were correlated with positive resection margins. Among the clinicopathological factors, tumor size of the invasive 
breast cancer and in situ components were significantly correlated with a positive resection margin. Multivariate analysis 
revealed that NME with or without mass was an independent predictor of positive resection margins (odds ratio [OR] = 7.00; 
p < 0.001). Strong BPE was a weak predictor of positive resection margins (OR = 2.59; p = 0.076).
Conclusion: Non-mass enhancement with or without mass is significantly associated with a positive resection margin in 
patients with breast cancer. In patients with NME, segmental distribution was significantly correlated with positive 
resection margins.
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INTRODUCTION
Overall survival after breast-conserving surgery (BCS) 
and adjuvant breast irradiation is equivalent to that after 
mastectomy for stage I or II breast cancer (1, 2). However, 
the probability of local recurrence is higher in patients 
treated with BCS compared with those undergoing radical 
mastectomy (2). A positive resection margin at the time 
of BCS is associated with a substantially higher local 
recurrence rate (3-5). A positive resection margin is defined 
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Histopathologic and Immunohistochemical Analysis
Final histopathological results of the surgical specimens 
were reviewed to determine the tumor size of both the 
invasive component alone, and the invasive and in situ 
components, the presence or absence of lobular histology, 
lymphovascular invasion (LVI), and immunohistochemical 
status. If the final diagnosis was DCIS, the size of the 
invasive component was recorded as zero. Estrogen receptor 
(ER) and progesterone receptor (PR) expression was 
recorded (negative or positive). HER2/neu (HER2) staging 
was scored as 0 (negative; no staining), 1+ (negative; 
faint/barely perceptible incomplete membrane staining), 2+ 
(equivocal; weak-to-moderate complete membrane staining 
in > 10% of the tumor cells or strong complete membrane 
staining in < 30% of the tumor cells), or 3+ (positive; 
strong complete membrane staining in > 30% of the tumor 
cells) according to the guidelines of the American Society 
of Clinical Oncology/College of American Pathologists (16). 
Tumors scoring 2+ required further examination using silver-
enhanced in situ hybridization (SISH) to measure HER2 
amplification. A HER2/chromosome 17 ratio greater than 2.2 
by SISH indicated HER2 positive status. 
TNM staging was also conducted based on the seventh 
American Joint Committee on Cancer guidelines (17). 
Sentinel node biopsies or axillary nodal dissections were 
performed, and the N stage was recorded. 
Lesion Localization and Evaluation of Resection Margin
Preoperative tumor localization for nonpalpable lesions 
was performed by two radiologists (with 5 years and 9 years 
of experience in breast imaging, respectively) with either 
mammographically or ultrasound-guided wire placement 
into the tumor. In cases of non-palpable tumors with 
microcalcifications, specimen mammography was performed 
to confirm adequate resection. Intraoperative margin 
excision and frozen section analysis were performed to 
evaluate intraoperative margins in all patients. A positive 
surgical margin was defined as the presence of tumor cells 
at the inked surface of the resected specimen. The margin 
was considered negative, in the absence of cancer cells on 
the inked surface of the resected specimen. We classified 
the following cases as a positive resection margin: 1) re-
excision for positive frozen section analysis during BCS, 
2) conversion from attempted BCS to mastectomy, and 3) 
requirement for further surgical excision.
by the presence of invasive carcinoma or ductal carcinoma 
in situ (DCIS) at the inked margin of the resected specimen 
(4, 6). In previous studies, several factors such as younger 
age, larger tumor size, positive lymph nodes, multifocal 
tumors, lobular histology, and the percentage of in situ 
components were associated with a positive resection 
margin (7-12).
Breast magnetic resonance imaging (MRI) has been 
widely used for the preoperative evaluation of tumor extent 
in patients with confirmed breast cancer. Previous studies 
reported that preoperative breast MRI altered the surgical 
management in approximately 20−30% of patients with 
breast cancer, leading to a decrease in reoperation rates 
and an increase in radical mastectomy rates (13, 14). 
The high sensitivity of breast MRI for cancer detection is 
presumed to improve the selection of patients for BCS and 
decrease the rates of a positive resection margin at the first 
BCS attempt (15). However, there is increasing concern 
that false-positive findings on preoperative MRI may lead 
to overtreatment in patients switching from BCS to radical 
mastectomy, without a clear survival benefit.
Therefore, it is important to determine the preoperative 
MRI findings and clinicopathological features associated 
with a positive resection margin during BCS. The purpose 
of our study was to determine the factors that are 
associated with a positive resection margin at the time of 
BCS in patients with breast cancer, with an emphasis on 
preoperative breast MRI findings.
MATERIALS AND METHODS
Patients
This retrospective study was approved by our Institution 
(Gangnam Severance Hospital) Review Board for clinical 
studies, and the need for obtaining individual consent 
from the subjects was waived. Between January 2015 and 
December 2015, we identified 153 consecutive women who 
had undergone BCS due to breast cancer, invasive cancer, 
or DCIS, and screened with preoperative MRI. Women 
receiving chemotherapy prior to surgery (n = 2), those who 
underwent local excisional biopsy before preoperative MRI 
(n = 24), and those lacking medical records associated with 
human epidermal growth factor receptor 2 (HER2) status (n 
= 7) were excluded. Finally, a total of 120 patients who had 
undergone BCS (mean age, 53.3 years; age range, 27−79 
years) were included in our study.
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MR Technique
Breast MRI was performed using a 3T system (Achieva, 
Philips Medical System, Best, the Netherlands; Discovery MR 
750, GE Healthcare, Waukesha, WI, USA) with a dedicated, 
sensitivity encoding (SENSE), four-channel breast coil. All 
images were acquired with bilateral axial views in the prone 
position. The protocol included turbo spin-echo T1- and 
T2-weighted images and T2-weighted fat suppressed spin-
echo series. Dynamic contrast-enhanced MRI was performed 
with one pre-contrast and five post-contrast dynamic series 
using a fat-suppressed T1-weighted gradient echo sequence 
(TR/TE: 4.9/2.4; matrix, 340 x 340; flip angle, 12°; field of 
view, 34 x 34 cm; slice thickness, 1.5 mm). The acquisition 
time of each post-contrast series was 74 seconds after a 
bolus injection of 0.1 mmol gadobutrol (Gadovist, Bayer 
Healthcare, Berlin, Germany) per kilogram of body weight 
via an automated injector (Nemoto, Nemoto Kyorindo, 
Tokyo, Japan), at a rate of 2 mL/s, followed by a 20-mL 
saline flush. After the examination, subtraction images were 
obtained by subtracting the unenhanced images from all 
contrast-enhanced images.
MRI Analysis
Two radiologists (with 5 years and 20 years of experience 
in breast MRI interpretation, respectively) reviewed the 
breast MR images in consensus according to the American 
College of Radiology breast imaging reporting and data 
system (ACR BIRADS) MRI lexicon (18). The largest 
diameters of enhancing lesions were measured in the axial 
plane of early post-contrast fat-suppressed T1-weighted 
images and subtraction images. Multifocal cancer was 
defined as the presence of two or more cancer lesions 
in the same quadrant, which were separated by normal 
breast parenchyma. In cases of multifocal lesions, the 
maximal diameter was not the sum of their diameters, but 
rather the single largest diameter measured. According 
to the ACR BIRADS MRI lexicon, enhancing lesions were 
divided into 2 categories: a mass including foci and non-
mass enhancement (NME). We categorized the 120 cases 
into 2 groups based on the patterns of enhancing lesions 
on breast MRI. These groups included: 1) mass without 
NME, 2) NME with or without mass. In patients with a 
mass, we additionally categorized the shape, margin, 
and internal enhancement of the mass according to the 
following criteria: 1) shape (oval, round, or irregular), 2) 
margin (circumscribed, irregular, or spiculated), and 3) 
internal enhancement (homogeneous, heterogeneous, rim 
enhancement, or dark internal septations). In patients 
with NME, we analyzed the distribution and internal 
enhancement patterns of the NME according to the 
following criteria: 1) distribution (focal, linear, segmental, 
or regional) and 2) internal enhancement patterns 
(homogeneous, heterogeneous, clumped, or clustered ring). 
We also assessed breast parenchymal enhancement (BPE) 
using post-contrast fat-suppressed T1-weighted images and 
subtraction images. BPE was categorized as minimal, mild, 
moderate, or marked, and dichotomized into weak (minimal 
or mild) or strong (moderate or marked) enhancement for 
statistical analysis. 
Statistical Analysis
The chi-squared test or Fisher’s exact test was used to 
identify the association between each of the preoperative 
breast MRI findings or clinicopathological factors and the 
rate of positive resection margins. An independent two-
sample t test was used for continuous normally distributed 
variables. Multivariate analysis was performed using logistic 
regression analysis of statistically significant variables (p 
< 0.100) via univariate analysis, and the odds ratios (ORs) 
were estimated. We considered p values less than 0.05 as 
statistically significant. SAS software (version 9.2, SAS 
Institute Inc., Cary, NC, USA) was used to perform the 
statistical analyses.
   
RESULTS
The final histopathological results of the surgical 
specimens revealed invasive ductal carcinoma in 88 cases, 
DCIS in 8, invasive cribriform carcinoma in 6, mucinous 
carcinoma in 5, invasive lobular carcinoma in 3, medullary 
carcinoma in 3, apocrine carcinoma in 2, microinvasive 
ductal carcinoma with lobular carcinoma in 1, invasive 
solid papillary carcinoma in 1, high-grade sarcoma in 1, 
glycogen-rich clear cell carcinoma in 1, and metaplastic 
carcinoma in 1 case.
Among the 120 patients, 31 (25.8%) showed a positive 
resection margin, and 89 (74.2%) had a negative resection 
margin. Among the 31 cases with a positive resection 
margin, 17 (54.8%) underwent re-excision for positive 
frozen section analysis during BCS, 8 (25.8%) received 
additional local excision, and 6 (19.4%) underwent 
converted total mastectomy from attempted BCS. The 
mean tumor size of invasive and in situ component was 
significantly larger in the positive resection margin group 
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compared with the negative resection margin group 
(2.7 cm vs. 1.8 cm; p = 0.015). Age, size of the invasive 
component of breast cancer, lobular histology, LVI, T stage, 
N stage, ER, PR, and HER2 status were not associated with 
positive resection margins (Table 1). The mean tumor size 
and multifocality of the tumor on MRI were associated 
with a positive resection margin (p = 0.048, p = 0.047, 
respectively). Patterns of enhancing lesions were also 
significantly associated with a positive resection margin 
(p < 0.001). Patients with a positive resection margin 
manifested a higher rate of NME with or without mass on 
preoperative breast MRI (61.3%) (Fig. 1). However, patients 
with a negative resection margin had a lower rate of NME 
with or without mass (14.6%). In cases with NME, the 
distribution was significantly associated with a positive 
resection margin (p = 0.024). Strong BPE was associated 
with a positive resection margin (p = 0.087) (Table 2). 
Univariate logistic regression analysis of 
clinicopathological features revealed that the size of the 
invasive as well as in situ component of the tumor was 
associated with a positive resection margin (OR = 1.97; p = 
0.004) (Table 3).
Table 4 summarizes the results of univariate logistic 
regression analysis of MRI findings. Tumor size, 
multifocality, and NME with or without mass were associated 
with positive resection margins (OR = 1.63; p = 0.015, OR 
= 3.42; p = 0.035, OR = 9.26; p < 0.001, respectively). In 
particular, NME with segmental distribution was strongly 
associated with a positive resection margin (OR = 11.96, p 
= 0.025).
Patterns of enhancing lesions were significantly 
associated with a positive resection margin. In terms 
of patterns of enhancing lesions, NME with or without 
mass was independently predictive of a positive resection 
margin (OR = 7.00; p < 0.001). Strong BPE was also a weak 
predictor of positive resection margin (OR = 2.59; p = 0.076) 
(Table 5).
   
DISCUSSION
Currently, BCS is the standard treatment for breast cancer 
Table 1. Analysis of Associations between Clinicopathologic 










Age (years) 51.3 ± 10.9 54.0 ± 11.4 0.250
Tumor size (cm)  
  (invasive component)
1.5 ± 1.2 1.6 ± 0.8 0.581
Tumor size (cm) (invasive 
  and in situ component)
2.7 ± 1.8 1.8 ± 0.8 0.015
Histology 0.274
Lobular   2 (6.5)   2 (2.3)
Other 29 (93.5) 87 (97.7)
Lymphovascular invasion 0.478
Present   7 (22.6) 15 (16.9)
Absent 24 (77.4) 74 (83.1)
T stage 0.289
Tis   3 (9.7)   5 (5.6)
T1 20 (64.5) 58 (65.2)
T2   7 (22.6) 26 (29.2)
T3   1 (3.2)   0 (0)
N stage 0.894
N0 23 (74.2) 68 (76.4)
N1   6 (19.4) 16 (18.0)
N2   2 (6.4)   4 (4.5)
N3   0 (0)   1 (1.1)
Estrogen receptor 0.491
Positive 21 (67.7) 66 (74.2)
Negative 10 (32.3) 23 (25.8)
Progesterone receptor 0.740
Positive 16 (51.6) 49 (55.1)
Negative 15 (48.4) 40 (44.9)
HER2 0.779
Positive   5 (16.1) 13 (14.6)
Negative 26 (83.9) 76 (85.4)
HER2 = human epidermal growth factor receptor 2, Tis =  
carcinoma in situ
Fig. 1. 69-year-old woman with invasive solid papillary 
carcinoma. Preoperative contrast-enhanced T1-weighted subtraction 
images show segmental clustered ring non-mass enhancement in 
outer portion of right breast. Patient underwent total mastectomy, 
which was converted from attempted breast-conserving surgery since 
positive resection margin was obtained from frozen section analysis. 
Size of invasive and in situ component of tumor was approximately 
3.7 cm. Patient tested positive for estrogen receptor, progesterone 
receptor and human epidermal growth factor receptor 2.
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are associated with a positive margin (7-12). Consistent 
with previous reports, the size of the invasive as well as 
in situ tumor component was associated significantly with 
a positive resection margin in our study (OR = 1.97; p = 
0.004). However, younger age and lobular histology (only 
4 cases out of 120) were not associated with positive 
resection margin in our study, probably due to the small 
number of cases.
The role of preoperative MRI in reducing the rate of 
positive resection margin in patients with breast cancer 
treated with BCS is disputed. Turnbull et al. (20), in a 
recent randomized controlled trial, reported that addition 
of preoperative breast MRI was not significantly associated 
with reduced reoperation rate. Houssami et al. (21), in 











Size on MRI (cm) 2.7 ± 2.2 1.9 ± 0.8 0.048
Multifocality 0.047
Yes   7 (22.6)   7 (7.9)
No 24 (77.4) 82 (92.1)
Patterns of enhancing lesions < 0.001
Mass without NME 12 (38.7) 76 (85.4)
NME with or without mass 19 (61.3) 13 (14.6)
Mass
Shape 0.923
Oval   9 (33.3) 25 (29.7)
Round   5 (18.5) 15 (17.9)
Irregular 13 (48.2) 44 (52.4)
Margin 0.222
Circumscribed 10 (37.1) 18 (21.4)
Irregular 11 (40.7) 48 (57.2)
Spiculated   6 (22.2) 18 (21.4)
Internal enhancement characteristics 0.470
Homogeneous   4 (14.8)   9 (10.8)
Heterogeneous 17 (63.0) 50 (60.3)
Rim enhancement   6 (22.2) 24 (28.9)
Dark internal septations   0 (0)   0 (0)
NME
Distribution 0.024
Focal   4 (21.0)   9 (69.2)
Linear   6 (31.6)   3 (23.1)
Segmental   8 (42.1)   1 (7.7)
Regional   1 (5.3)   0 (0)
Internal enhancement patterns 0.475
Homogeneous   1 (5.3)   0 (0)
Heterogeneous   4 (21.0)   6 (46.15)
Clumped 11 (57.9)   6 (46.15)
Clustered ring   3 (15.8)   1 (7.7)
BPE 0.087
Weak 20 (64.5) 71 (79.8)
Strong 11 (35.5) 18 (20.2)
BPE = breast parenchymal enhancement, MRI = magnetic resonance 
imaging, NME = non-mass enhancement
in its early stages. However, a positive resection margin at 
the time of BCS is associated with a considerably higher 
risk of local tumor recurrence (3, 4). The rate of positive 
resection margin in our study was 25.8% (31/120) which 
was within the reported range of 20−70% in the literature 
(3, 19). Larger tumor size, lobular histology, presence of in 
situ components, younger age, multifocal lesions, and LVI 
Table 3. Univariate Logistic Regression Analysis of 
Clinicopathologic Factors for Predicting Positive Resection 
Margin
OR 95% CI P
Age (years) 0.98 0.94−1.02 0.249
Tumor size (cm) 
  (invasive component)
0.86 0.54−1.35 0.503
Tumor size (cm) (invasive and 
  in situ component)
1.97 1.24−3.11 0.004
Histology
Lobular 3.00 0.40−22.27 0.283
Other Ref
Lymphovascular invasion




T1 0.55 0.12−2.49 0.438
T2 0.45 0.09−2.30 0.334
T3 4.79 0.04−559.56 0.519
N stage
N0 Ref
N1 1.15 0.41−3.25 0.795
N2 1.62 0.29−9.18 0.586
N3 0.93 0.01−92.69 0.974
Estrogen receptor
Positive 0.73 0.30−1.78 0.492
Negative Ref
Progesterone receptor
Positive 0.87 0.38−1.98 0.741
Negative Ref
HER2
Positive 1.12 0.37−3.46 0.838
Negative Ref
CI = confidence interval, OR = odds ratio, Ref = reference
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a meta-analysis of 9 studies, reported that exposure to 
preoperative breast MRI increased the overall mastectomy 
rate (25.5% vs. 18.2%; OR, 1.54 [p < 0.001]; adjusted 
OR, 1.51 [p < 0.001]) and failed to reduce the rate of re-
excision surgery in patients with initial breast conservation 
(11.6% vs. 11.4%; OR, 1.02 [p = 0.87]; adjusted OR, 0.95 
[p = 0.71]). On the other hand, Pengel et al. (22) reported 
that preoperative MRI was significantly associated with a 
lower rate of incomplete excision in patients with invasive 
ductal carcinoma. Mann et al. (23) found that preoperative 
breast MRI reduced the rate of re-excision without 
increasing the mastectomy rate in patients with invasive 
lobular carcinoma.
With regard to the MRI features associated with resection 
margin positivity after BCS, according to Kim et al. (24), 
the single NME group showed the highest re-excision rate 
after BCS (22.2%, p = 0.02). Jang et al. (25) found that a 
tumor size exceeding 5 cm (OR = 3.81), NME (OR = 2.96), 
and multifocal lesions (OR = 2.54) on preoperative MRI 
were positively associated with re-excision. For NME lesions, 
the segmental distribution pattern predicted re-excision 
(OR = 10.53) (25). Similar to a previous study, NME with or 
without mass was an independent predictor of a positive 
resection margin compared with mass without NME (OR 
= 7.00, p < 0.001). Notably, the segmental distribution 
of NME was strongly associated with a positive resection 
margin (OR = 11.96, p = 0.025). The association between 
NME and resection margin positivity might be explained 
by the presence of a DCIS component manifesting as NME. 
DCIS more commonly presented as NME than mass and many 
DCIS lesions exhibit segmental or ductal distribution and a 
clustered ring or clumped internal enhancement (26-28). 
Furthermore, many studies have reported that the presence 
of a DCIS component was significantly associated with a 
positive resection margin (25, 29-32). Thus, radiologists 
should be aware that NME on preoperative breast MRI 
increases the possibility of subsequent positive resection 
margin status.
In this study, multifocal cancer on MRI was correlated 
with positive resection margin in univariate analysis, but 
not in multivariate analysis, which might be explained by 
the routine use of multiple wire localization for multifocal, 
nonpalpable lesions in our hospital. 
Additionally, a strong BPE was associated with a positive 
resection margin with borderline significance (OR = 2.59, 
p = 0.76) in our study, similar to a previous study in which 
strong BPE was a significant independent factor for positive 
Table 4. Univariate Logistic Regression Analysis of MRI Findings 
for Predicting Positive Resection Margin
OR 95% CI P
Size on MRI (cm) 1.63 1.10−2.43 0.015
Multifocality
Yes 3.42 1.09−10.71 0.035
No Ref
Patterns of enhancing lesions
Mass without NME Ref




Round 0.93 0.26−3.29 0.905
Irregular 0.82 0.31−2.19 0.693
Margin
Circumscribed Ref
Irregular 0.41 0.15−1.14 0.087
Spiculated 0.60 0.18−2.00 0.406
Internal enhancement characteristics
Homogeneous Ref
Heterogeneous 0.77 0.21−2.81 0.686




Linear 3.92 0.65−23.66 0.136
Segmental 11.96 1.37−104.62 0.025
Regional 6.89 0.06−813.36 0.428
Internal enhancement patterns
Homogeneous Ref
Heterogeneous 0.23 0.01−25.38 0.538
Clumped 0.58 0.01−60.78 0.818
Clustered ring 0.76 0.01−116.21 0.916
BPE
Weak Ref
Strong 2.17 0.88−5.33 0.091
Table 5. Multivariate Analysis of MRI Findings for Predicting 
Positive Resection Margin
OR 95% CI P
Size on MRI (cm) 1.24 0.83−1.84 0.288
Multifocality
Yes 2.04 0.52−7.99 0.308
No Ref
Patterns of enhancing lesions
Mass without NME Ref
NME with or without mass 7.00   2.38−20.63 < 0.001
BPE
Weak Ref
Strong 2.59 0.91−7.42 0.076
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resection margin (OR = 2.39) (33). BPE varies in degree 
and distribution in different patients as well as in the same 
patient over time. Moderate or marked BPE may yield false-
positive or false-negative results, and has been associated 
with abnormal interpretation compared with minimal or 
mild BPE, especially in the presence of focal, regional, 
or asymmetric BPE (34, 35). Small additional masses or 
NME around the index cancer may be masked by adjacent 
enhancing breast tissue leading to a false-negative 
interpretation (35, 36).
There are several limitations to this study. First, because 
of its retrospective design, patient selection bias might 
have occurred. We identified 153 consecutive patients with 
breast cancer who had undergone preoperative MRI and 
BCS. The patients whose initial surgical plan was switched 
from BCS to mastectomy due to unfavorable preoperative 
MRI findings were excluded. Furthermore, 33 (21.6%) of 
the 153 patients were excluded because they underwent 
chemotherapy prior to surgery, had a local excisional biopsy, 
or lacked medical records showing HER2 status. Second, 
we did not correlate the MRI findings with the pathologic 
findings comprehensively. Further studies correlating MRI 
and pathological findings are needed.
In conclusion, this study found that NME with or 
without mass detected on preoperative breast MRI was 
an independent predictive factor for a positive resection 
margin. More specifically, NME with segmental distribution 
was strongly correlated with a positive resection margin. 
In addition, strong BPE was associated with a positive 
resection margin with borderline significance. Among 
clinicopathologic factors, the size of the invasive and in situ 
component of the tumor was significantly associated with 
a positive resection margin. These factors facilitate patient 
selection and determination of the extent of resection 
during BCS.
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